The FDA on February 28, 2019 approved HERCEPTIN HYLECTA®, a combination of HERCEPTIN® (Trastuzumab), a HER2/neu receptor antagonist, and Hyaluronidase, an endoglycosidase, for the treatment of HER2 overexpressing breast cancer. HERCEPTIN HYLECTA® is a product of Genentech Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
